Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
100%(4 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_2
3
60%
Ph phase_1
2
40%

Phase Distribution

2

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
3(60.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(4)
Terminated(1)

Detailed Status

Completed4
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
80.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (40.0%)
Phase 23 (60.0%)

Trials by Status

completed480%
terminated120%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_1

GSK1325756 Relative Bioavailability Study in Healthy Elderly Subjects

NCT03457727
terminatedphase_2

Randomized Study Evaluating the Effect of Danirixin on Neutrophil Extracellular Traps (NETs) in Chronic Obstructive Pulmonary Disease (COPD)

NCT03250689
completedphase_2

Danirixin Dose Ranging Study in Participants With Chronic Obstructive Pulmonary Disease (COPD)

NCT03034967
completedphase_2

Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations

NCT02130193
completedphase_1

Evaluation of Danirixin (GSK1325756) Inhibition of CD11b Cell Surface Expression

NCT02201303

Clinical Trials (5)

Showing 5 of 5 trials
NCT03457727Phase 1

GSK1325756 Relative Bioavailability Study in Healthy Elderly Subjects

Completed
NCT03250689Phase 2

Randomized Study Evaluating the Effect of Danirixin on Neutrophil Extracellular Traps (NETs) in Chronic Obstructive Pulmonary Disease (COPD)

Terminated
NCT03034967Phase 2

Danirixin Dose Ranging Study in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT02130193Phase 2

Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations

Completed
NCT02201303Phase 1

Evaluation of Danirixin (GSK1325756) Inhibition of CD11b Cell Surface Expression

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5